Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03869892




Registration number
NCT03869892
Ethics application status
Date submitted
23/02/2018
Date registered
11/03/2019
Date last updated
18/11/2023

Titles & IDs
Public title
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
Scientific title
An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candidatE for Intensive Therapy (SOLSTICE Study)
Secondary ID [1] 0 0
2017-004059-22
Secondary ID [2] 0 0
CL3-95005-006
Universal Trial Number (UTN)
Trial acronym
SOLSTICE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Colorectal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Trifluridine/tipiracil hydrochloride (S95005)
Treatment: Drugs - Capecitabine
Treatment: Other - Bevacizumab experimental
Treatment: Other - Bevacizumab control

Experimental: S95005 + Bevacizumab -

Active comparator: Capecitabine + Bevacizumab -


Treatment: Drugs: Trifluridine/tipiracil hydrochloride (S95005)
Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.

Treatment: Drugs: Capecitabine
Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.

Treatment: Other: Bevacizumab experimental
Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.

Treatment: Other: Bevacizumab control
Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
Up to 24 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to 24 months
Secondary outcome [2] 0 0
Overall response rate (ORR)
Timepoint [2] 0 0
Up to 24 months
Secondary outcome [3] 0 0
Disease control rate (DCR)
Timepoint [3] 0 0
Up to 24 months
Secondary outcome [4] 0 0
Duration of response (DoR)
Timepoint [4] 0 0
Up to 24 months
Secondary outcome [5] 0 0
Time to treatment failure (TTF)
Timepoint [5] 0 0
Up to 24 months

Eligibility
Key inclusion criteria
1. Has definitive histologically confirmed adenocarcinoma of the colon or rectum (all other histological types are excluded). Primary tumour localisation must be known.
2. RAS status based on local biological assessment of tumour biopsy must be available. If RAS status is not available at the time of randomisation, tumour biopsy must be available for RAS status determination (based on local biological assessment).
3. Patient is not a candidate for standard full dose combination chemotherapy with irinotecan or oxaliplatin
4. Patient is not a candidate for curative resection of metastatic lesions.
5. No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.
6. ECOG (Eastern Cooperative Oncology Group) performance status =2.
7. Adequate organ function (renal, haematological, hepatic, coagulation) as described in the study protocol'
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
8. Pregnancy, breastfeeding or possibility of becoming pregnant during the study.
9. Participation in another interventional study within 4 weeks prior to the randomisation .
10. Patients who have not recovered from clinically relevant non-hematologic CTCAE grade = 3 toxicity of previous anticancer therapy prior to the randomisation.
11. Symptomatic central nervous system metastases.
12. Major surgery within 4 weeks prior to the randomisation.

Exclusion criteria related to S 95005 administration:
13. History of allergic reactions attributed to compounds of similar composition to S 95005 or any of its excipients.
14. Any contraindication present in the SmPC of trifluridine/tipiracil

Exclusion criteria related to bevacizumab administration:
15. Any contraindication present in the SmPC of bevacizumab

Exclusion criteria related to capecitabine administration:
16. Any contraindication present in the SmPC of capecitabine

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/03/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/06/2024
Actual
Sample size
Target
Accrual to date
Final
856
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Blacktown Hospital Cancer and Haematology Centre - Blacktown
Recruitment hospital [2] 0 0
Frankston Private Peninsula and Southeast Oncology Group - Frankston
Recruitment hospital [3] 0 0
Lake Macquarie Private Hospital - Gateshead
Recruitment hospital [4] 0 0
St George Hospital St George Hospital Cancer Care Centre - Kogarah
Recruitment hospital [5] 0 0
Adventist HealthCare Integrated Cancer Centre - Wahroonga
Recruitment hospital [6] 0 0
Southern Medical Day Care Centre - Wollongong
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
3199 - Frankston
Recruitment postcode(s) [3] 0 0
2290 - Gateshead
Recruitment postcode(s) [4] 0 0
2217 - Kogarah
Recruitment postcode(s) [5] 0 0
2076 - Wahroonga
Recruitment postcode(s) [6] 0 0
2500 - Wollongong
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Berazategui
Country [2] 0 0
Argentina
State/province [2] 0 0
Buenos Aires
Country [3] 0 0
Argentina
State/province [3] 0 0
Ciudad Autonoma de Buenos aires
Country [4] 0 0
Argentina
State/province [4] 0 0
Ciudad Autónoma de Buenos Aires
Country [5] 0 0
Argentina
State/province [5] 0 0
La Rioja
Country [6] 0 0
Argentina
State/province [6] 0 0
Mendoza
Country [7] 0 0
Argentina
State/province [7] 0 0
Santa Fe
Country [8] 0 0
Argentina
State/province [8] 0 0
Tucumán
Country [9] 0 0
Austria
State/province [9] 0 0
Graz
Country [10] 0 0
Austria
State/province [10] 0 0
Innsbruck
Country [11] 0 0
Austria
State/province [11] 0 0
Linz
Country [12] 0 0
Austria
State/province [12] 0 0
Salzburg
Country [13] 0 0
Austria
State/province [13] 0 0
St. Poelten
Country [14] 0 0
Austria
State/province [14] 0 0
Wien
Country [15] 0 0
Brazil
State/province [15] 0 0
Barretos
Country [16] 0 0
Brazil
State/province [16] 0 0
Belo Horizonte
Country [17] 0 0
Brazil
State/province [17] 0 0
Brasília
Country [18] 0 0
Brazil
State/province [18] 0 0
Ijuí
Country [19] 0 0
Brazil
State/province [19] 0 0
Porto Alegre
Country [20] 0 0
Brazil
State/province [20] 0 0
Salvador
Country [21] 0 0
Brazil
State/province [21] 0 0
Santo André
Country [22] 0 0
Brazil
State/province [22] 0 0
São José Do Rio Preto
Country [23] 0 0
Brazil
State/province [23] 0 0
São Paulo
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Burgas
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Gabrovo
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Plovdiv
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Varna
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Vratsa
Country [30] 0 0
Czechia
State/province [30] 0 0
Brno
Country [31] 0 0
Czechia
State/province [31] 0 0
Ostrava
Country [32] 0 0
Czechia
State/province [32] 0 0
Praha
Country [33] 0 0
Denmark
State/province [33] 0 0
Aalborg
Country [34] 0 0
Denmark
State/province [34] 0 0
Herning
Country [35] 0 0
Denmark
State/province [35] 0 0
Kobenhavn
Country [36] 0 0
Denmark
State/province [36] 0 0
Odense
Country [37] 0 0
Estonia
State/province [37] 0 0
Tallinn
Country [38] 0 0
Estonia
State/province [38] 0 0
Tartu
Country [39] 0 0
France
State/province [39] 0 0
Avignon
Country [40] 0 0
France
State/province [40] 0 0
Besancon
Country [41] 0 0
France
State/province [41] 0 0
Brest
Country [42] 0 0
France
State/province [42] 0 0
Lyon
Country [43] 0 0
France
State/province [43] 0 0
Montbeliard
Country [44] 0 0
France
State/province [44] 0 0
Nice
Country [45] 0 0
France
State/province [45] 0 0
Paris
Country [46] 0 0
France
State/province [46] 0 0
Pessac
Country [47] 0 0
France
State/province [47] 0 0
Toulouse
Country [48] 0 0
Germany
State/province [48] 0 0
Berlin
Country [49] 0 0
Germany
State/province [49] 0 0
Luebeck
Country [50] 0 0
Germany
State/province [50] 0 0
Muenchen
Country [51] 0 0
Hungary
State/province [51] 0 0
Budapest
Country [52] 0 0
Hungary
State/province [52] 0 0
Debrecen
Country [53] 0 0
Hungary
State/province [53] 0 0
Gyula
Country [54] 0 0
Hungary
State/province [54] 0 0
Gyor
Country [55] 0 0
Hungary
State/province [55] 0 0
Kecskemét
Country [56] 0 0
Hungary
State/province [56] 0 0
Nyíregyháza
Country [57] 0 0
Hungary
State/province [57] 0 0
Pécs
Country [58] 0 0
Hungary
State/province [58] 0 0
Szeged
Country [59] 0 0
Hungary
State/province [59] 0 0
Szolnok
Country [60] 0 0
Hungary
State/province [60] 0 0
Szombathely
Country [61] 0 0
Hungary
State/province [61] 0 0
Zalaegerszeg
Country [62] 0 0
Ireland
State/province [62] 0 0
Cork
Country [63] 0 0
Ireland
State/province [63] 0 0
Dublin
Country [64] 0 0
Italy
State/province [64] 0 0
Cagliari
Country [65] 0 0
Italy
State/province [65] 0 0
Cremona
Country [66] 0 0
Italy
State/province [66] 0 0
Napoli
Country [67] 0 0
Italy
State/province [67] 0 0
Padova
Country [68] 0 0
Italy
State/province [68] 0 0
Pisa
Country [69] 0 0
Italy
State/province [69] 0 0
Potenza
Country [70] 0 0
Italy
State/province [70] 0 0
Reggio Emilia
Country [71] 0 0
Italy
State/province [71] 0 0
Roma
Country [72] 0 0
Italy
State/province [72] 0 0
Rozzano (mi)
Country [73] 0 0
Italy
State/province [73] 0 0
San Giovanni Rotondo
Country [74] 0 0
Italy
State/province [74] 0 0
Vicenza
Country [75] 0 0
Latvia
State/province [75] 0 0
Riga
Country [76] 0 0
Lithuania
State/province [76] 0 0
Kaunas
Country [77] 0 0
Lithuania
State/province [77] 0 0
Klaipeda
Country [78] 0 0
Lithuania
State/province [78] 0 0
Vilnius
Country [79] 0 0
Netherlands
State/province [79] 0 0
Arnhem
Country [80] 0 0
Netherlands
State/province [80] 0 0
Dordrecht
Country [81] 0 0
Netherlands
State/province [81] 0 0
Eindhoven
Country [82] 0 0
Netherlands
State/province [82] 0 0
Rotterdam
Country [83] 0 0
Netherlands
State/province [83] 0 0
Tilburg
Country [84] 0 0
Netherlands
State/province [84] 0 0
Uden
Country [85] 0 0
Poland
State/province [85] 0 0
Bialystok
Country [86] 0 0
Poland
State/province [86] 0 0
Gdansk
Country [87] 0 0
Poland
State/province [87] 0 0
Konin
Country [88] 0 0
Poland
State/province [88] 0 0
Olsztyn
Country [89] 0 0
Poland
State/province [89] 0 0
Opole
Country [90] 0 0
Poland
State/province [90] 0 0
Poznan
Country [91] 0 0
Poland
State/province [91] 0 0
Tomaszów Mazowiecki
Country [92] 0 0
Poland
State/province [92] 0 0
Lódz
Country [93] 0 0
Portugal
State/province [93] 0 0
Almada
Country [94] 0 0
Portugal
State/province [94] 0 0
Coimbra
Country [95] 0 0
Portugal
State/province [95] 0 0
Lisboa
Country [96] 0 0
Portugal
State/province [96] 0 0
Loures
Country [97] 0 0
Portugal
State/province [97] 0 0
Porto
Country [98] 0 0
Romania
State/province [98] 0 0
Bucuresti
Country [99] 0 0
Romania
State/province [99] 0 0
Cluj-Napoca
Country [100] 0 0
Romania
State/province [100] 0 0
Craiova
Country [101] 0 0
Romania
State/province [101] 0 0
Iasi
Country [102] 0 0
Romania
State/province [102] 0 0
Sibiu
Country [103] 0 0
Romania
State/province [103] 0 0
Timisoara
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Arkhangel'sk
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Krasnodar
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Kursk
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Moscow
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Omsk
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Pyatigorsk
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Rostov-on-Don
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Ryazan'
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Saint Petersburg
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Samara
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Sochi
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Tomsk
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Yaroslavl
Country [117] 0 0
Slovakia
State/province [117] 0 0
Bratislava
Country [118] 0 0
Slovakia
State/province [118] 0 0
Košice
Country [119] 0 0
Spain
State/province [119] 0 0
Alicante
Country [120] 0 0
Spain
State/province [120] 0 0
Badalona
Country [121] 0 0
Spain
State/province [121] 0 0
Barcelona
Country [122] 0 0
Spain
State/province [122] 0 0
Córdoba
Country [123] 0 0
Spain
State/province [123] 0 0
Hospitalet de Llobregat
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Spain
State/province [125] 0 0
Santander
Country [126] 0 0
Spain
State/province [126] 0 0
Sevilla
Country [127] 0 0
Spain
State/province [127] 0 0
Valencia
Country [128] 0 0
Spain
State/province [128] 0 0
Zaragoza
Country [129] 0 0
Sweden
State/province [129] 0 0
Falun
Country [130] 0 0
Sweden
State/province [130] 0 0
Jönköping
Country [131] 0 0
Sweden
State/province [131] 0 0
Solna
Country [132] 0 0
Sweden
State/province [132] 0 0
Umeå
Country [133] 0 0
Sweden
State/province [133] 0 0
Örebro
Country [134] 0 0
Ukraine
State/province [134] 0 0
Cherkasy
Country [135] 0 0
Ukraine
State/province [135] 0 0
Dnipro
Country [136] 0 0
Ukraine
State/province [136] 0 0
Kharkiv
Country [137] 0 0
Ukraine
State/province [137] 0 0
Kyiv
Country [138] 0 0
Ukraine
State/province [138] 0 0
Lviv
Country [139] 0 0
Ukraine
State/province [139] 0 0
Odesa
Country [140] 0 0
Ukraine
State/province [140] 0 0
Vinnytsya
Country [141] 0 0
Ukraine
State/province [141] 0 0
Zaporozhye
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Aberdeen
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Bristol
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Leeds
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Leicester
Country [146] 0 0
United Kingdom
State/province [146] 0 0
London
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Manchester
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Rhyl
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Other
Name
Institut de Recherches Internationales Servier
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
ADIR, a Servier Group company
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.
Trial website
https://clinicaltrials.gov/study/NCT03869892
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Thierry ANDRE, PhD
Address 0 0
Medical Oncology departement Saint-Antoine hospital (Paris France 75012)
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03869892